-
July 19, 2012
Novo Nordisk has suffered another setback in its bid to get approval in the USA for its ultra long-acting insulin degludec and insulin combination analogue degludec/aspart after regulators said the drugs will face an advisory panel
Full story
-
June 26, 2012
Pfizer and Bristol-Myers Squibb have suffered a setback on the news that regulators in the USA have delayed giving the green light to the firms' much-touted bloodthinner Eliquis
Full story
-
June 08, 2012
Novo Nordisk will have to wait a fair bit longer for US approval for its ultra long-acting insulin degludec and insulin combination analogue degludec/aspart after regulators put back their review on the drugs
Full story
-
April 18, 2012
Generic drugmakers, especially Sun Pharmaceutical Industries, are celebrating a landmark ruling by the US Supreme Court which has ruled in favour of the Indian drugmaker in its long-running patent battle with Novo Nordisk over the latter's diabetes drug Prandin
Full story
-
April 11, 2012
While Vivus' share price slid on the news that regulators in the USA have put back their final decision on Qnexa by three months, analysts at Cowen & Co are still confident of approval for the obesity drug
Full story
-
March 30, 2012
Almirall and Forest Laboratories will have to wait a bit longer before getting US approval for their chronic obstructive pulmonary disease drug aclidinium bromide
Full story
-
March 01, 2012
Bristol-Myers Squibb and Pfizer will have to wait a bit longer before getting US approval for their anti-clotting drug Eliquis
Full story
-
November 18, 2011
Takeda is going to have to wait a bit longer to get US approval for its type 2 diabetes therapy alogliptin, and the fixed-dose combination of the drug plus the Japanese drugmaker's Actos
Full story
-
February 07, 2011
AstraZeneca's chances of getting a quick approval in the USA for Brilinta after regulators said it needs another six months to review the much-touted anti-clotting agent. The firm has also ended development of its prostate cancer drug zibotentan as monotherapy
Full story
-
January 10, 2011
AstraZeneca's vandetanib has suffered a setback in the USA after regulators said they need more time to assess the drug as a treatment for non-operable locally advanced or metastatic medullary thyroid cancer (MTC).
Full story